Comparison of Four Carbapenemase Detection Methods for blaKPC-2 Variants

Carbapenemase detection is essential for the appropriate treatment of CRE infections. Several clinical laboratories have begun using relevant carbapenemase assays such as mCIM (modified carbapenem inactivation method) and eCIM (EDTA carbapenem inactivation method), the APB/EDTA method, NG-test Carba 5, and GeneXpert Carba-R to detect carbapenemases. ABSTRACT Recently, various blaKPC-2 variants resistant to ceftazidime-avibactam have begun to emerge in clinical settings, but it is unclear which testing method is most appropriate for detecting these variants. Strains were subjected to antimicrobial susceptibility testing using the broth microdilution method. Four carbapenemase detection methods, modified carbapenem inactivation method (mCIM) and EDTA carbapenem inactivation method (eCIM), APB/EDTA (carbapenemase inhibitor APB [3-aminophenylboronic acid] and EDTA enhancement method), NG-test Carba 5, and GeneXpert Carba-R were used to try to detect KPC-2 variants in 19 Klebsiella pneumoniae isolates. Among those blaKPC-2 variants, blaKPC-33-, blaKPC-35-, blaKPC-71-, blaKPC-76-, blaKPC-78-, and blaKPC-79-positive isolates accounted for 26.3% (5/19), 15.8% (3/19), 5.3% (1/19), % 42.1% (8/19), 5.3% (1/19), and 5.3% (1/19), respectively. All 19 K. pneumoniae carrying blaKPC-2 variants showed resistance to ceftazidime-avibactam (MICs:16 to >64 mg/L), and 14 strains were susceptible to imipenem (MICs: 0.25 to 1 mg/L). None of the blaKPC-2 variants could be detected using either the mCIM or the APB/EDTA method, while five strains carrying blaKPC-2 variants (blaKPC-35, blaKPC-78, and blaKPC-79) tested KPC positive when using NG-test Carba 5. However, GeneXpert Carba-R was able to detect blaKPC-2 variants (harboring blaKPC-33, blaKPC-35, blaKPC-71, blaKPC-76, blaKPC-78, and blaKPC-79) carried by all 19 K. pneumoniae. The emergence of new KPC variants poses an increased challenge for carbapenemase detection methods, and laboratories should use the appropriate assays to accurately detect these variants. IMPORTANCE Carbapenemase detection is essential for the appropriate treatment of CRE infections. Several clinical laboratories have begun using relevant carbapenemase assays such as mCIM and eCIM, the APB/EDTA method, NG-test Carba 5, and GeneXpert Carba-R to detect carbapenemases. Nevertheless, some of these methods may have limitations for detecting blaKPC-2 variants. Additionally, there has been little relevant research on evaluate the differences between these standard methods for detecting blaKPC-2 variants. Therefore, we investigated the reliability of these classic methods for assessing 19 K. pneumoniae with blaKPC-2 variants. Our results showed that none of the blaKPC-2 variants could be detected using either the mCIM or APB/EDTA method, while five strains (harboring blaKPC-35, blaKPC-78,and blaKPC-79) tested KPC positive when using NG-test Carba 5. GeneXpert Carba-R could detect six blaKPC-2 variants carried by all 19 K. pneumoniae. This study may be valuable for clinical laboratories in their efforts to test for various blaKPC-2 variants.

[1]  K. Kazmierczak,et al.  Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017 , 2021, Antimicrobial agents and chemotherapy.

[2]  C. McElheny,et al.  Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseri , 2021, Antimicrobial agents and chemotherapy.

[3]  A. di Caro,et al.  Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae. , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  Shirong Li,et al.  Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  F. Hu,et al.  Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China , 2020, Frontiers in Cellular and Infection Microbiology.

[6]  Tetsuya Matsumoto,et al.  Comparative Evaluation of five Assays for Detection of Carbapenemases with a Proposed Scheme for Their Precise Application. , 2020, The Journal of molecular diagnostics : JMD.

[7]  Robin Patel,et al.  Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. , 2020, The Lancet. Infectious diseases.

[8]  D. Nicolau,et al.  Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology , 2020, Current Infectious Disease Reports.

[9]  T. Naas,et al.  Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. , 2019, The Journal of antimicrobial chemotherapy.

[10]  F. Hu,et al.  Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa , 2019, Antimicrobial Agents and Chemotherapy.

[11]  N. Woodford,et al.  Evaluation of the NG-Test CARBA 5 multiplex immunochromatographic assay for the detection of KPC, OXA-48-like, NDM, VIM and IMP carbapenemases , 2018, The Journal of antimicrobial chemotherapy.

[12]  T. Naas,et al.  A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae , 2018, The Journal of antimicrobial chemotherapy.

[13]  B. Kreiswirth,et al.  Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature , 2017, Open forum infectious diseases.

[14]  L. Schouls,et al.  The Carbapenem Inactivation Method (CIM), a Simple and Low-Cost Alternative for the Carba NP Test to Assess Phenotypic Carbapenemase Activity in Gram-Negative Rods , 2015, PloS one.

[15]  Michael Bell,et al.  Vital Signs: Carbapenem-Resistant Enterobacteriaceae , 2013, MMWR. Morbidity and mortality weekly report.

[16]  V. Esnault,et al.  Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients. , 2012, The Journal of infection.

[17]  S. Pournaras,et al.  A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. , 2010, The Journal of antimicrobial chemotherapy.

[18]  D. Paterson,et al.  Simple Disk-Based Method for Detection of Klebsiella pneumoniae Carbapenemase-Type β-Lactamase by Use of a Boronic Acid Compound , 2008, Journal of Clinical Microbiology.

[19]  Y. Carmeli,et al.  Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant Klebsiella pneumoniae Strains in an Israeli Hospital , 2007, Antimicrobial Agents and Chemotherapy.

[20]  G. Rahav,et al.  Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.